Ranbaxy gets Canada's nod to mkt anti-hypertension drug
Pharma company Ranbaxy Laboratories today said it has received the final approval of the Canadian drug regulator Therapeutic Products Directorate (TPD) to market and manufacture 'Ran-Amlodipine tablets', used in treating hypertensions.
The company has got the approval for Ran-Amlodipine (Amlodipine Besylate tablets) in 5 and 10 mg strengths, through its wholly-owned subsidiary Ranbaxy Pharmaceuticals- Canada Inc (RPCI), Gurgaon-based (RPCI) said in a statement.
"We look forward to marketing both strengths of Ran-Amlodipine tablets at affordable prices that will be beneficial to both the Canadian healthcare system, and most importantly to Canadian patients," RPCI President Paul Drake said.
The total market for Amlodipine Besylate tablets in Canada is 456 million Canadian dollars.